Neuropharmacological intervention on the pituitary-hypothalamic relationship.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D004876:Ergot Alkaloids / Q000494:pharmacology; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology*; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D018377:Neurotransmitter Agents / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology; D011388:Prolactin / Q000378:metabolism*; D011389:Prolactin Release-Inhibiting Factors / Q000502:physiology; D051381:Rats; D011954:Receptors, Dopamine / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D013972:Thyrotropin / Q000378:metabolism*
D014150:Antipsychotic Agents; D004876:Ergot Alkaloids; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D012701:Serotonin; D007980:Levodopa; D011388:Prolactin; D013972:Thyrotropin; D013006:Growth Hormone; D011389:Prolactin Release-Inhibiting Factors; D004298:Dopamine; D009638:Norepinephrine